Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study

UK approves Wegovy pill in major shift in obesity treatment options

Approval is based on results from the phase 3 OASIS 4 clinical trial

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Wegovy pill smashes past 3mn prescriptions in under six months in US

The company said Wegovy hit its first one million prescriptions within 12 weeks of availability

Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials

The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Novo Nordisk launches Wegovy pill in UAE in first global rollout outside US

The move signals a major expansion in access to next-generation weight-loss therapies

Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors

The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks